Novartis Ag Patent Portfolio Statistics

Novartis Ag

Profile Summary

This article summarizes the perfomance of the assignee in the recent years. The overall statistics for this portfolio help to analyze the areas where the assignee is performing well. The filing trend, perfomance across the tech centers and the perfomance of the recent applications has been mentioned below. All the stats are calculated based on the perfomance in USPTO.

How does the overall patent portfolio of Novartis Ag look like?

Total Applications: 7,191
Granted Patents: 4,879
Grant Index 73.87 %
Abandoned/Rejected Applications: 1,726 (26.13%)
In-Process Applications: 583
Average Grant Time: 2.92 Years
Average Office Actions: 1.77

Which Technology Area Novartis Ag is filing most patents in? (Last 10 years)

Art Unit Definition Total Applications
1624 Organic Chemistry 459
1626 Organic Chemistry 425
1625 Organic Chemistry 302
1645 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 288
1628 Organic Chemistry 215

How many patents are Novartis Ag filing every year?

Year Total Applications
2022 0*
2021 119*
2020 204
2019 258
2018 371

*The drop in the number of applications filed in last two years compared to previous years is because applications can take up to 18 months to get published

Recently filed patent applications of Novartis Ag in USPTO?

Publication number:
Application number: 17/522,568


Publication date:
Applicant: Novartis Ag
Inventors: Christian Leist

Publication number: US20210393671A1
Application number: 17/463,391

The present disclosure provides salts of lipoic acid choline ester (LACE), crystalline forms thereof, and methods of use thereof. The present disclosure further provides pharmaceutical compositions of LACE salts and methods of use thereof.

Publication date: 2021-12-23
Applicant: Novartis Ag
Inventors: Tingying Zhu

Publication number: US20210386824A1
Application number: 17/410,307

The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.

Publication date: 2021-12-16
Applicant: Novartis Ag
Inventors: Craig Stephen Weldon

How are Novartis Ag’s applications performing in USPTO?

Application Number Title Status Art Unit Examiner
17/522,568 Cell Culture Medium Application Undergoing Preexam Processing 1653
17/463,391 Pharmaceutical Compositions Of Lipoic Acid Choline Ester Salts And Methods Of Treatment Using Same Docketed New Case – Ready for Examination OPAP Central, Docket
17/410,307 Nucleic Acids Encoding Fgf21-Fc Fusion Proteins Docketed New Case – Ready for Examination OPAP Central, Docket
17/432,868 Combination Therapies Of Egfrviii Chimeric Antigen Receptors And Pd-1 Inhibitors Sent to Classification contractor OPAP Central, Docket
17/401,770 Application Unlock Using A Connected Physical Device And Transfer Of Data Therebetween Docketed New Case – Ready for Examination OPAP Central, Docket